Work

A Multicenter Analysis of Outcomes, Toxicities, and Patterns of Use with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

Year: 2021

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2021-151971

Authors: Peter A. Riedell, Jamie Brower, Loretta Nastoupil, Miguel-Angel Perales, Richard T. Maziarz, Joseph P. McGuirk, Veronika Bachanova, Wei-Ting Hwang, Stephen J. Schuster, Michael R. Bishop, David L. Porter

Institutions: University of Chicago, University of Pennsylvania, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, OHSU Knight Cancer Institute, University of Kansas Medical Center, University of Minnesota

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3213053919

Cites:

Cited by: 5

Related to: 10